An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
Terminated · Phase 1 · NCT06568614
Conditions: Advanced or Metastatic MTAP-deleted Solid Tumors
At a glance
- Research payments reported, 2025
- $24,750
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 29
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BG-89894 (drug)
- Dates
- Started 2024-10-12; completion 2026-04-13
- Results posted
- Not yet
This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.
From ClinicalTrials.gov, last updated 2026-05-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $24,750 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Next Virginia, LLC $24,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.